


## (rel)-Eglumegad

Cat. No.:	HY-18941B		
CAS No.:	176027-90-0		
Molecular Formula:	C <sub>8</sub> H <sub>11</sub> NO <sub>4</sub>		
Molecular Weight:	185.18		
Target:	mGluR		
Pathway:	GPCR/G Protein; Neuronal Signaling		
Storage:	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### BIOLOGICAL ACTIVITY

<b>Description</b>	(rel)-Eglumegad ((rel)-LY354740) is a relative configuration of Eglumegad (HY-18941). Eglumegad is a highly potent and selective group II (mGlu2/3) receptor agonist with EC <sub>50</sub> s of 5 and 24 nM for transfected human mGlu2 and mGlu3 receptors, respectively <sup>[1]</sup> .
<b>IC<sub>50</sub> &amp; Target</b>	mGluR2 <sup>[1]</sup>

### REFERENCES

- [1]. Boerner T, et al. The group II metabotropic glutamate receptor agonist LY354740 and the D2 receptor antagonist haloperidol reduce locomotor hyperactivity but fail to rescue spatial working memory in GluA1 knockout mice. *Eur J Neurosci.* 2017 Apr;45(7):912-
- [2]. Orlando R, et al. Levels of the Rab GDP dissociation inhibitor (GDI) are altered in the prenatal restrain stress mouse model of schizophrenia and are differentially regulated by the mGlu2/3 receptor agonists, LY379268 and LY354740. *Neuropharmacology.* 2014
- [3]. Procaccini C, et al. Reversal of novelty-induced hyperlocomotion and hippocampal c-Fos expression in GluA1 knockout male mice by the mGluR2/3 agonist LY354740. *Neuroscience.* 2013 Oct 10;250:189-200
- [4]. Lee Y, et al. The mGlu2/3 receptor agonist LY354740 suppresses immobilization stress-induced increase in rat prefrontal cortical BDNF mRNA expression. *Neurosci Lett.* 2006 May 8;398(3):328-32.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA